AP
NVCR icon

Antipodes Partners’s NovoCure NVCR Stock Holding History

Antipodes Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,119
Closed -$19.9K – 130
2025
Q2 		$19.9K Buy
+1,119
New +$19.5K ﹤0.01% 99

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Antipodes Partners's NVCR Position: Q3 2025 in Review

Antipodes Partners sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 1,119 shares — an estimated $19.9K sold.

Antipodes Partners first reported a position in NVCR in Q2 2025 and held it in 1 quarter. The position peaked at $19.9K in Q2 2025. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • Antipodes Partners reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
  • Antipodes Partners sold 1,119 NovoCure shares in Q3 2025, an estimated $19.9K.
  • Antipodes Partners first reported a position in NovoCure in Q2 2025 and held it in 1 quarter.
  • Antipodes Partners's NovoCure position peaked at $19.9K in Q2 2025.
  • 244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Antipodes Partners's 13F filing for Q3 2025, filed 10 Nov 2025.